Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 365

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

Open access
Prokhnevska, Nataliya, Cardenas, Maria A., Valanparambil, Rajesh M., Sobierajska, Ewelina, Barwick, Benjamin G., Jansen, Caroline, Reyes Moon, Adriana, Gregorova, Petra, delBalzo, Luke, Greenwald, Rachel, Bilen, Mehmet Asim, Alemozaffar, Mehrdad, Joshi, Shreyas, Cimmino, Cara, Larsen, Christian, Master, Viraj, Sanda, Martin, Kissick, Haydn·2023·Immunity

Abstract

SUMMARY Improvements in tumor immunotherapies depend on better understanding of the anti-tumor T cell response. By studying human tumor-draining lymph nodes (TDLNs), we found that activated CD8+ T cells in TDLNs shared functional, transcriptional, and epigenetic traits with TCF1+ stem-like cells in the tumor. The phenotype and TCR overlap suggested that these TDLN cells were precursors to tumor-resident stem-like CD8+ T cells. Murine tumor models revealed that tumor-specific CD8+ T cells were activated in TDLNs but lacked an effector phenotype. These stem-like cells migrated into the tumor, where additional co-stimulation from antigen-presenting cells drove effector differentiation. This model of CD8+ T cell activation in response to cancer is different from that of canonical CD8+ T cell activation to acute viruses, and it proposes two stages of tumor-specific CD8+ T cell activation: initial activation in TDLNs and subsequent effector program acquisition within the tumor after additional co-stimulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2022.12.002

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 83 references

Cited by

See all 365

Metadata

Authors
Prokhnevska, N., Cardenas, M. A., Valanparambil, R. M., Sobierajska, E., Barwick, B. G., Jansen, C., Reyes Moon, A., Gregorova, P., delBalzo, L., Greenwald, R., Bilen, M. A., Alemozaffar, M., Joshi, S., Cimmino, C., Larsen, C., Master, V., Sanda, M., & Kissick, H.
Venue
Immunity
Publisher
Elsevier BV
Published
2023-01
Volume
56
Issue
1
Pages
107-124.e5
ISSN
1074-7613 (ISSN-L)
OpenAlex
W4313312023
Cited by
365
References
83
FWCI
20.64
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. https://app.cochat.ai/papers/10.1016/j.immuni.2022.12.002
The paper
Prokhnevska, N., Cardenas, M. A., Valanparambil, R. M., Sobierajska, E., Barwick, B. G., Jansen, C., Reyes Moon, A., Gregorova, P., delBalzo, L., Greenwald, R., Bilen, M. A., Alemozaffar, M., Joshi, S., Cimmino, C., Larsen, C., Master, V., Sanda, M., & Kissick, H. (2023). CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. https://doi.org/10.1016/j.immuni.2022.12.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.